Why Brocade, Cempra, Apple, and Two Other Stocks Are in Spotlight Today

Although Goldman Sachs is unquestionably the top bank of Wall Street right now, the investment bank apparently has its limits, as CNBC recently reported that (according to its sources) Apple Inc. (NASDAQ:AAPL) isn’t interested in bidding for Time Warner at this time. Goldman Sachs was previously rumored to have been pushing Apple to make a rival bid for Time Warner after the media giant agreed to sell itself to AT&T. A total of 116 top funds tracked by Insider Monkey held $10.68 billion worth of Apple Inc. (NASDAQ:AAPL)’s stock, which accounted for 2.00% of the float on June 30, versus 152 funds and $14.82 billion, respectively, on March 31.

Follow Apple Inc. (NASDAQ:AAPL)

Cempra Inc (NASDAQ:CEMP) shares are 46% in the red after the FDA released background information for the advisory committee scheduled to review solithromycin. What might have spooked some investors was a particular section saying:

“Despite the differences in chemical structure, the hepatic adverse effects seen with solithromycin during its development program exceed the pre-marketing hepatic signal seen with telithromycin. Significant gaps in knowledge of the hepatic toxicity profile of solithromycin exist. For example, the likelihood of serious idiosyncratic liver injury in a larger population and the impact of prior sensitization to macrolides on solithromycin-induced liver injury are unknown.”

Some traders speculate the ‘unknown’ phrase might hint at the need for more studies. A total of 14 funds had a bullish position in Cempra Inc (NASDAQ:CEMP) at the end of the second quarter, unchanged from the previous quarter.

Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)

Disclosure: none